# Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants

> **NCT06738017** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **BioMarin Pharmaceutical** · enrollment: 6 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **DRUG:** BMN 349
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06738017
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-21
- **Primary completion:** 2026-08-19
- **Final completion:** 2026-08-19
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06738017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06738017, "Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06738017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*